A life-saving meningococcal vaccine covering all five common strains of the deadly disease could soon be available thanks to ...

ACIP recommends pentavalent meningococcal vaccine Penmenvy (meningococcal Groups A, B, C, W, and Y vaccine) for individuals 10 through 25 years of age.

Also active in the category is Sanofi, which sells MenACWY vaccines Menactra and MenQuadfi, lacking coverage of the B serogroup considered the most common cause of meningococcal disease in the US.

This recommendation, if adopted, will allow for vaccination against serogroups A, B, C, W, and Y in fewer doses, could simplify meningococcal vaccination delivery and could improve immunization ...

Background: Given the broad age range across which the quadrivalent meningococcal ... routine vaccines did not reduce immune responses to diphtheria, tetanus, poliovirus, hepatitis B, Haemophilus ...

Cite this: Neurological Adverse Events of Immunization: Experience With an Aluminum Adjuvanted Meningococcal B Outer Membrane Vesicle Vaccine - Medscape - Oct 01, 2007. Adverse events following ...

Both Novartis and Pfizer have serogroup B vaccines in development. Globally, infants are at the highest risk of infection with meningococcal disease, and so vaccines that can be administered to ...

The ACIP voted that Penmenvy may be used as part of the adolescent meningococcal vaccination schedule as an alternative to separate administration of MenACWY and MenB. The Centers for Disease ...